 | |
| Clinical data | |
|---|---|
| Trade names | Rocornal, Avantrin, Travisco |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.035.834 |
| Chemical and physical data | |
| Formula | C10H15N5 |
| Molar mass | 205.265 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Trapidil is used in the treatment of chronic stableangina pectoris. It is currently marketed in Japan under the brand name Rocornal.[1]
Ananalog was assigned the codename AR 12-456.[2]
Based on cell freein vitro activity assays, trapidil at therapeutic concentrations causes selective phosphorylation of cellular proteins through positive modulation of regulatory subunit RII(α/β) containingprotein kinase A (PKA).[3][4] At higher, non-physiologically relevant concentrations, which are generally not achieved after administration of therapeutic doses, non-selective inhibition of phosphodiesterases occurs.[4] Further, the previous documented activities as an antagonist ofplatelet-derived growth factor[5] are abolished when a PKA inhibitor is administered, suggesting that these noted activities are PKA mediated.[4] At these higher concentrations,[6] additional effects have been noted includingvasodilation and inhibition of platelet aggregation[7][8]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |